Single-Dose HPV Vaccine Evaluation Consortium
Since 2018, the Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH, has gathered and evaluated data from clinical trials, observational studies, and modeling analyses regarding the value of a single-dose HPV vaccination schedule to protect against cervical cancer.
Results are emerging from several clinical trials evaluating the ability of a single dose of HPV vaccine to elicit a strong immune response against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.
The data accumulated to date support the World Health Organization (WHO) endorsement of a single-dose HPV vaccination schedule for substantially reducing the incidence of HPV-attributable cervical precancer and cancer for the primary target of girls aged 9-14 years old and for young women aged 15-20 years old.
Explore and share the evidence using the resources below.
Resources from the Single-Dose HPV Vaccine Evaluation Consortium
Frequently asked questions about single-dose HPV vaccination
This four-page FAQ document provides answers to common questions on current evidence and policy landscape for single-dose HPV vaccination.
Fact sheet: Evidence on single-dose HPV vaccination
This two-page brief provides a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.
Slide deck:
This PowerPoint deck outlines the evidence base in support of a single-dose vaccination schedule. Use the presentation as a guide for meetings with key decision-makers.
External resources
Publications on single-dose HPV vaccination
- Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nature Medicine. December 2023.
- Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. BMC Medicine. August 2023.
- Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania. Vaccine. January 2023.
- Efficacy of single-dose HPV vaccination among young African women. NEJM Evidence. April 2022
- Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet Global Health. October 2022.
- Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. The Lancet Global Health. March 2022.
- Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncology. November 2021.
- Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine. February 2021.
- Evaluation of durability of a single dose of the bivalent HPV vaccine: The CVT trial. Journal of the National Cancer Institute. October 2020.